Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06818656 · ClinicalTrials.gov registry record

The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS

A clinical trial, sponsored by Brain Inflammation Collaborative.

Completed
Registry status
65
Enrollment target

NCT06818656: Completed study, sponsored by Brain Inflammation Collaborative.

NCT06818656 is a clinical trial that has completed, run by Brain Inflammation Collaborative. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06818656 has completed, sponsored by Brain Inflammation Collaborative.

COMPLETED
Registry status
65 participants
Enrollment target

Study Summary

The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with thinking and mood that can sometimes be symptoms of conditions like autoimmune disease, infection-associated chronic conditions like Long COVID, ME/CFS, PANDAS, PANS, and other illnesses. Your contribution to this research will allow us to better describe these symptoms and understand what causes them, how they develop, and how they can best be treated and prevented. This study seeks to assess how PANDAS/PANS affects the financial well-being of families who pursue IVIG treatment, as well as the overall health and quality of life of children with the condition. By gathering data through this survey, we aim to gain important insights into the economic consequences of treating - or not treating - PANS with IVIG, including how it impacts parents' ability to work and children's ability to attend school. Key Eligibility Criteria * Aged 2-89, U.S. resident, fluent in English, and have access to computer and/or smartphone * Suspected or confirmed diagnosis of PANS/PANDAS * Have received IVIG OR have sought and/or been prescribed IVIG but have not received it

Primary Outcome

This survey asks respondents (and/or their parent/legal guardian) about aspects of IVIG treatment related to medical encounters, treatment access, financial impacts, insurance coverage, and the functional and emotional effects of PANS/PANDAS.

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2025-03-01
Est. Completion 2025-06-19
Brain Inflammation Collaborative

2 total trials

What the finished NCT06818656 record still lists

NCT06818656 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT06818656 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06818656 about?

NCT06818656 is a clinical study titled "The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS". The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with...

What is the current status of trial NCT06818656?

This trial is currently completed. The enrollment target is 65 participants. The study started on 2025-03-01. Estimated completion is 2025-06-19.

Who is sponsoring clinical trial NCT06818656?

This trial is sponsored by Brain Inflammation Collaborative, which has 2 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06818656, the US trial registry maintained by the National Library of Medicine. NCT06818656 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.